Alnylam Pharmaceuticals
ALNY
#581
Rank
โ‚น2.977 T
Marketcap
โ‚น23,006
Share price
-0.94%
Change (1 day)
84.59%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -โ‚น20.04 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚น2.24 Billion. , an increase over its 2023 earnings that were of -โ‚น26.77 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -โ‚น20.19 Billion-24.59%
2023 -โ‚น26.77 Billion-67.84%
2022 -โ‚น83.22 Billion36.93%
2021 -โ‚น60.77 Billion-8.04%
2020 -โ‚น66.08 Billion-15.66%
2019 -โ‚น78.36 Billion12.23%
2018 -โ‚น69.82 Billion62.91%
2017 -โ‚น42.86 Billion17.78%
2016 -โ‚น36.39 Billion43.44%
2015 -โ‚น25.37 Billion60.69%
2014 -โ‚น15.79 Billion98.2%
2013 -โ‚น7.97 Billion
2011 -โ‚น4.7 Billion27.48%
2010 -โ‚น3.69 Billion-10.92%
2009 -โ‚น4.14 Billion95.77%
2008 -โ‚น2.12 Billion
2006 -โ‚น3.39 Billion-9.13%
2005 -โ‚น3.73 Billion34.74%
2004 -โ‚น2.77 Billion36.79%
2003 -โ‚น2.03 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚น51.44 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น409.61 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น22.34 B-210.72%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น0.89 Billion-95.60%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น3.55 Billion-82.43%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.168 T-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น680.59 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น24.17 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel